Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Demand & Sales Analysis by Product & Protein Type The global recombinant protein market will witness a robust CAGR of 10.12%, valued at $1.65 billion in 2021, expected to appreciate and reach $3.93 billion by 2030, confirms Strategic Market Research. The region of North America comprehensively accounted for the most significant market share throughout the estimated time frame of 2020-2030. Recombinant proteins are encoded by recombinant DNA, cloned into an expression vector that allows the gene to be expressed and messenger RNA to be translated. The production of a mutant protein can result from recombinant DNA technology modification of the gene. Novel therapeutics for severe chronic illnesses such as cancer and other uncommon diseases are developed using recombinant proteins. According to the report of OECD(Organisation for Economic Co-operation and Development), Health at a Glance, on an average, across 27 OECD countries, about one-third of the population aged 15 years & above were reported to be living with two or more chronic diseases, including cancer, myocardial infarction, chronic respiratory issues, congestive heart failure and diabetes. Interferons, interleukins, tumour necrosis factor, Recombinant human insulin, Recombinant human growth hormone, Recombinant blood clotting factor VIII, proteinase k, recombinant mabs, recombinant protein antibody, HEK293-derived cell lines, eukaryotic cells, Escherichia coli, recombinant hormones and others are categorized based on recombinant DNA (rDNA) technology. Market Drivers - A Rise in The Government Funding and An Increase In R&D Spending by Pharmaceutical Companies, The Growing Prevalence of Chronic Diseases, Rising Number of Regulatory Approvals, Need for Reducing Viral Infections Due to extended research times and regulatory delays, the R&D business has always been capital-intensive. R&D expenditures take up a significant portion of worldwide spending. Governments recognize R&D as an important component of a country's growth, international competitiveness, and public benefit. As a result, R&D spending and funding have steadily increased. According to Global R&D Funding Forecast, Global life science R&D spending will expand by 3.6 per cent to USD 2.3 trillion by 2019. Chronic illnesses are on the rise, resulting in high demand for recombinant protein therapies, as recombinant proteins are among the few established treatments for such disorders. According to GLOBOCAN, in Mexico, in 2020, there were approximately 195,499 new cancer cases identified and 90,222 cancer-related deaths. In the last three years, the cases of regulatory approvals have grown significantly, thereby increasing the number of alternatives available to individuals with uncommon conditions, including haemophilia and other bleeding disorders. Companies were able to extend their product ranges and obtain a competitive edge as a result of these approvals hence driving the recombinant plasma protein therapeutics market. The desire to reduce the high frequency of viral illnesses, including human papillomavirus, hepatitis B, CoVid-19, and others, is driving up demand for vaccinations all around the world. According to the HPV information centre, Annual HPV incidence instances were greatest in emerging nations such as China and India. The rising prevalence of diseases like cerebral apoplexy, multiple sclerosis, neutropenia, thrombocytopenia, anaemia, hepatitis, rheumatoid arthritis, asthma, Crohn's disease, and dwarfism is increasing the demand for mRNA, thrombolytic drugs, recombinant protein drugs, and treatment methods such as cancer therapy, mammalian cells culture, recombinant protein western blot, recombinant DNA, animal cells in culture, glycosylation, biotherapeutics, bioengineering, etc. which in turn are augmenting the overall market growth significantly across the globe. Restraints - The Cost of Recombinant Proteins is Decreasing Price erosion happens when many competitors join a small market and provide similar products with little differentiation. The price of such things looks to be slowly falling in these circumstances, thus reducing the recombinant protein market growth. Trends and Opportunities - Emerging Markets and Technological Advancements Due to the emerging region's diverse healthcare markets, rising incidence of infectious and chronic diseases, and increasing R&D initiatives to develop innovative proteomic and genomic techniques, the Asia Pacific region is expected to have potential growth opportunities for market players in the coming years. According to a study issued by the National Bureau of Statistics, China's overall R&D expenditure was roughly 2.79 trillion yuan (about $441.13 billion) in 2021, rising at a rate of almost 14.2 % per year. Advancements have aided in expanding the recombinant protein market from the technology perspective in different sectors related to or aiding recombinant protein synthesis. Alternative expression technologies, such as mammalian cell expression, baculovirus expression, and E.coli expression, and the creation of alternative cell lines and improved cell culture systems, have all simplified and streamlined recombinant protein processes. Furthermore, advances in bioreactor systems have increased the output of the product in a shorter amount of time. According to the National Centre for Biotechnology Information (NCBI), single-use bioreactors were used by 65.6 per cent of clinical scale producers and 42 per cent of commercial manufacturers to enhance bioprocessing. Furthermore, the geriatric population, rising income levels, improvements in healthcare infrastructure, rising healthcare spending, and growing APAC nations' low-cost manufacturing advantages are projected to entice market participants to invest in the area. Along with this, the recombinant clotting protein market and recombinant non-glycosylated protein market are expected to rise at a CAGR of 7.6% and 8.9%, respectively. Market Analysis Of Different Segments Covered in the Report Based on Product Growth factors (Blood and Tissue) and chemokines Structural proteins Kinase proteins Human insulin Regulatory proteins Membrane proteins Recombinant metabolic enzymes Adhesion molecules and receptors Immune response proteins Other recombinant proteins Based on Type Biologics Vaccines Cell & gene therapy Based on End-User Pharmaceutical & biopharmaceutical companies Biotechnology companies Academic research institutes Contract research organizations Other end-users Regional Coverage Analysis North America USA Canada Mexico Rest of North America Europe France Germany U.K Spain Italy Rest of Europe Asia Pacific China India Japan Australia Rest of APAC LAMEA Brazil Saudi Arabia South Africa Rest of LAMEA Product Analysis & Insights Based on the Product, Growth factors and chemokines has the largest market share. The application of growth factors and chemokines in many research areas such as chemotaxis, neurobiology, wound healing, immunology, transplantation, apoptosis, cancer, HIV/AIDS, COVID-19, cell culture, and stem cell research accounts for a major portion of the growth factors and chemokines market. According to the Centres for Disease Control and Prevention, United States will have roughly 34,800 new HIV infections year 2020. According to the same source, over 13% of HIV-positive people in the United States are uninformed of their status and are needed to be diagnosed as soon as possible. Type Analysis & Insights Based on the Type, The Biologics segment accounted for robust market coverage. This is due to the rising frequency and incidence of target illnesses, increased research and development, and a robust recombinant protein-based biologics development pipeline. According to Global R&D Funding Forecast, Global life science R&D spending will expand by 3.6 per cent to USD 2.3 trillion by 2019. End-User Analysis & Insights Based on the End-User, the Pharmaceutical & biopharmaceutical companies segment has the largest market. The strong demand for recombinant proteins for prognostic, predictive, or diagnostic identification and the measurement of biomarkers in drug research and development accounts for a substantial portion of this market. Furthermore, factors such as the expiration of patents on blockbuster pharmaceuticals and increased expenditures on drug discovery promote the segment's growth. Regional Analysis & Insights Based on Regions, North America has the largest market share and is the fastest-growing market for soft tissue repair. The rising prevalence of chronic & infectious illnesses, increasing R&D investment, expanding research activities, favourable government financing in food production (agriculture), and the prominent companies in this area are all factors contributing to North America's big share of the worldwide market. According to American Cancer Society, around 1,735,350 new cancer cases were identified in the United States, with 609,640 persons dying from cancer. Recombinant Protein Market Report Coverage Report Attribute Details Forecast Period 2021 - 2030 Market size value in 2021 USD 1.65 billion Revenue forecast in 2030 USD 3.93 billion Growth rate CAGR of approximately 10.12% Base year for estimation 2021 Unit USD Billion, CAGR (2021 - 2030) Segmentation By Product, By Type, By Region By Product Growth factors (Blood and Tissue) and chemokines, Structural proteins, Kinase proteins, Human insulin, Regulatory proteins, Membrane proteins, Recombinant metabolic enzymes, Adhesion molecules and receptors, Immune response proteins, Other recombinant proteins. By Type Biologics, Vaccines, Cell & gene therapy By Region Asia Pacific, North America, Europe, LAMEA Country Scope U.S., Canada, France, Germany, U.K., China, Japan, India, South Korea, Mexico, Brazil, U.A.E. etc. Company Usability Profiles Thermo Fisher Scientific, Inc. (the US), R&D Systems (US), Abcam plc (UK), Merck KGaA (Germany), and Proteintech Group, Inc. (the US), Janssen-Cilag Pty Ltd., Aviva Systems Biology, Bio-Techne Corporation (US), Elpiscience BioPharma, Eli Lilly and co., GigaGen Inc. Global Recombinant Protein Market Competitive Landscape Analysis The competitive landscape analysis provides information about the crucial competitors prevailing in the worldwide market environment. The comparison is performed based on overall revenue generation, market initiatives, company overview, investment in R&D, company financials, company strengths and weaknesses, global presence, production capacity, production sites and facilities, market potential, etc. Thermo Fisher Scientific, Inc. (US) R&D Systems (US) Abcam plc (UK) Merck KGaA (Germany) Proteintech Group, Inc. (US) Janssen-Cilag Pty Ltd. Aviva Systems Biology Bio-Techne Corporation (US) Elpiscience BioPharma Eli Lilly and co. GigaGen Inc. U Protein Express Recent Developments In November 2020, Eli Lilly and Company received an Emergency Use Authorization (EUA) for bamlanivimab (LY-CoV555) 700 mg, an experimental neutralizing antibody, for the treatment of mild to moderate COVID-19 in adults and children. In December 2020, Bio-Techne Corporation (US) and Elpiscience BioPharma collaborated. Elpiscience would have access to Bio-large Techne's product range of antibodies for use in the development of preclinical, clinical, and commercial biopharmaceuticals as part of this agreement, which is intended to produce anticancer treatments. In September 2020, GigaGen Inc., in collaboration with Goodwin Biotechnology, Inc., and Waisman Biomanufacturing, began large-scale manufacturing of GIGA-2050, its first-in-class recombinant hyperimmune drug for COVID 19. In June 2020, The Recombinant Antibody Network (RAN), which includes researchers from the University of Toronto, UC San Francisco, & the University of Chicago, successfully partnered with Celgene, a Bristol-Myers Squibb company, to develop high-performance recombinant antibodies against a variety of targets in human cells. In February 2020, Merck KGaA (Germany) and Donghao Lansheng (Group) Co., Ltd. worked on a project (China). This partnership aimed to test a new import policy in China. It will make it easier for Merck to clear research items for biomedical innovation and analytical purposes via customs in the future. Various Recombinant Protein Products That the Market Leaders Are Manufacturing Name of the Product Function Key Players Eprex Used for the treatment of anaemia Janssen-Cilag Pty Ltd. Bamlanivimab (LY-CoV555) 700 mg Treatment of mild to moderate COVID-19 Eli Lilly Co. GIGA-2050 Hyperimmune drug for COVID 19. GigaGen Inc. Frequently Asked Question About This Report What are the most dominant regions of the market? Based on Regions, North America has the largest market share and is the fastest-growing market industry. The rising prevalence of chronic & infectious illnesses, increasing R&D investment, expanding research activities, favourable government financing, and growing companies in this area are all factors contributing to North Americas big share of the worldwide market. What is recombinant protein? Recombinant protein is a modified type of protein produced in various methods to create huge amounts of proteins, change gene sequences, and make commercially viable products. List ten recombinant proteins? The list of 10 recombinant proteins are as follows: Insulin, Interferon-a, Interferon -ß, Coagulation factor VII, Coagulation factor IX, DNAase I, Anti-thrombin VIII, Interferon B., Human recombinant growth hormone, Tissue plasminogen activator. What are the recombinant protein market growth? The global recombinant protein market is expected to grow at a compound annual growth rate (CAGR) of 10.12 % from 2021 to 2030 to reach USD 3.93 Billion by 2030. What are examples of recombinant proteins? Some examples of recombinant proteins are Growth factors and chemokines, Structural proteins, Kinase proteins, Human insulin, Regulatory proteins, Membrane proteins, Recombinant metabolic enzymes, Adhesion molecules and receptors, and Immune response proteins. What is the first recombinant protein approved in the market? In 1982, recombinant human insulin became the first recombinant protein utilized in medicine. Which are the prominent market players across the globe? The most vital players in the industry are Thermo Fisher Scientific, Inc. (the US), R&D Systems (US), Abcam plc (UK), Merck KGaA (Germany), and Proteintech Group, Inc. (the US), Janssen-Cilag Pty Ltd., Aviva Systems Biology, Bio-Techne Corporation (US), Elpiscience BioPharma, Eli Lilly and co., GigaGen Inc. How big is the recombinant protein market? The global recombinant protein market size was $ 1.65 Bn in 2021 and is predicted to reach $ 3.93 Bn by 2030, with a CAGR of 10.12 %. Sources https://www.oecd.org/health/health-at-a-glance/ https://www.rdworldonline.com/global-funding-forecast-predicts-growth-of-rd-spending-worldwide/ https://gco.iarc.fr/today/data/factsheets/populations/484-mexico-fact-sheets.pdf https://hpvcentre.net/statistics/reports/IND.pdf http://www.stats.gov.cn/english/PressRelease/202201/t20220127_1827065.html https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8340809/ 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at market size by bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size by Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Market: Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Global Recombinant Protein Market 4.2.1 Global Market, 2020 – 2028 (USD Million) 4.3 Based on Product 4.3.1 Global Market, Based on Product, 2021 - 2030 (USD Million) 4.4 Based on Type 4.4.1 Global Market, Based on Type, 2021 - 2030 (USD Million) 4.5 Based on Region 4.5.1 Global Market, Based on Region, 2021 - 2030 (USD Million) 4.6 Value Chain Analysis 4.7 Market Variable Analysis 4.7.1 Market Drivers Analysis 4.7.2 Market Restraints Analysis 4.8 Business Environment Analysis Tool 4.8.1 Market PEST analysis 4.8.2 Market Porter’s analysis 4.9 Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 On Market 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. Technology Analysis 5.11.1. Trends in Technology (2014-2020) 5.11.2. Trends in Technology (2021-2028) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By region, By Countries) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers Facial Implants Manufacturing Sites, Area Served, Product Type 6.3. Market Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Global Market: Based on Product Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021-2030) 7.3. Growth factors (Blood and Tissue) and chemokines 7.3.1. Growth factors (Blood and Tissue) and chemokines market, 2021 - 2030 (USD Million) 7.4. Structural proteins 7.4.1. Structural proteins market, 2021 - 2030 (USD Million) 7.5. Kinase proteins 7.5.1. Kinase proteins market, 2021 - 2030 (USD Million) 7.6. Human insulin 7.6.1. Human insulin market, 2021 - 2030 (USD Million) 7.7. Regulatory proteins 7.7.1. Regulatory proteins market, 2021 - 2030 (USD Million) 7.8. Membrane proteins 7.8.1. Membrane proteins market, 2021 - 2030 (USD Million) 7.9. Recombinant metabolic enzymes 7.9.1. Recombinant metabolic enzymes market, 2021 - 2030 (USD Million) 8.0. Adhesion molecules and receptors 8.0.0. Adhesion molecules and receptors market, 2021 - 2030 (USD Million) 8.1. Immune response proteins 8.1.0. Immune response proteins market, 2021 - 2030 (USD Million) 8.2. Other s 8.2.0. Other s market, 2021 - 2030 (USD Million) 8. Global Market: Based on Type 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2021-2030) 8.3. Biologics 8.3.1. Biologics, 2021 - 2030 (USD Million) 8.4. Vaccines 8.4.1. Vaccines market, 2021 - 2030 (USD Million) 8.5. Cell & gene therapy 8.5.1 Cell & gene therapy market, 2021 - 2030 (USD Million) 9. Global Market: Regional Outlook 9.1 North America 9.1.1. North America Market, By Product, 2021 - 2030 (USD Million) 9.1.4. North America Market, By Type, 2021 - 2030 (USD Million) 9.1.5. North America Market, by Country, 2021 - 2030 (USD Million) 9.1.4.1. U.S. 9.1.4.1.1. U.S. Market, By Product, 2021 - 2030 (USD Million) 9.1.4.2. Canada 9.1.4.2.1. Canada Market, By Product, 2021 - 2030 (USD Million) 9.1.4.2.2. Canada Market, By Region, 2021 - 2030 (USD Million) 9.1.4.2.3. Canada Market, By Type, 2021 - 2030 (USD Million) 9.2. Europe 9.2.1. Europe Market, By Product, 2021 - 2030 (USD Million) 9.2.2. Europe Market, by By Type, 2021 - 2030 (USD Million) 9.2.5. Europe Market, by country, 2021 - 2030 (USD Million) 9.2.4.1 U.K. 9.2.4.1.1. U.K. Market, By Product, 2021 - 2030 (USD Million) 9.2.4.1.2. U.K. Market, By Type, 2021 - 2030 (USD Million) 9.2.4.1.3. U.K. Market, by Region, 2021 - 2030 (USD Million) 9.2.4.2. Germany 9.2.4.2.1. Germany Market, By Product, 2021 - 2030 (USD Million) 9.2.4.2.2. Germany Market, By Type, 2021 - 2030 (USD Million) 9.2.4.2.3. Germany Market, by Region, 2021 - 2030 (USD Million) 9.2.4.3. France 9.2.4.3.1. France Market, By Product, 2021 - 2030 (USD Million) 9.2.4.3.2. France Market, By Region, 2021 - 2030 (USD Million) 9.2.4.3.3. France Market, By Type, 2021 - 2030 (USD Million) 9.2.4.4. Rest of Europe 9.2.4.4.1. Rest of Europe Market, By Product, 2021 - 2030 (USD Million) 9.2.4.4.2. Rest of Europe Market, By Region, 2021 - 2030 (USD Million) 9.2.4.4.3. Rest of Europe Market, By Type, 2021 - 2030 (USD Million) 9.3. Asia Pacific 9.3.1. Asia Pacific Market, By Product, 2021 - 2030 (USD Million) 9.3.2. Asia Pacific Market, By Type, 2021 - 2030 (USD Million) 9.3.5. Asia Pacific Market, by country, 2021 - 2030 (USD Million) 9.3.4.1. China 9.3.4.1.1. China Market, By Product, 2021 - 2030 (USD Million) 9.3.4.1.2. China Market, By Region, 2021 - 2030 (USD Million) 9.3.4.1.3. China Market, By Type, 2021 - 2030 (USD Million) 9.3.4.2. India 9.3.4.2.1. India Market, By Product, 2021 - 2030 (USD Million) 9.3.4.2.2. India Market, By Region, 2021 - 2030 (USD Million) 9.3.4.2.3. India Market, By Type, 2021 - 2030 (USD Million) 9.3.4.3. Japan 9.3.4.3.1. Japan Market, By Product, 2021 - 2030 (USD Million) 9.3.4.3.3. Japan Market, By Type, 2021 - 2030 (USD Million) 9.3.4.4. South Korea 9.3.4.4.1. South Korea Market, By Product, 2021 - 2030 (USD Million) 9.3.4.4.3. South Korea Market, By Type, 2021 - 2030 (USD Million) 9.3.4.5. Rest of ASIA PACIFIC 9.3.4.5.1. Rest of ASIA PACIFIC Market, By Product, 2021 - 2030 (USD Million) 9.3.4.5.3. Rest of ASIA PACIFIC Market, By Type, 2021 - 2030 (USD Million) 9.4. Latin America 9.4.1. Latin America Market, By Product, 2021 - 2030 (USD Million) 9.4.3. Latin America Market, By Type, 2021 - 2030 (USD Million) 9.4.4. Latin America Market, by country, 2021 - 2030 (USD Million) 9.4.4.1. Brazil 9.4.4.1.1. Brazil Market, By Product, 2021 - 2030 (USD Million) 9.4.4.1.3. Brazil Market, By Type, 2021 - 2030 (USD Million) 9.4.4.2. Mexico 9.4.4.2.1. Mexico Market, By Product, 2021 - 2030 (USD Million) 9.4.4.2.3. Mexico Market, By Type, 2021 - 2030 (USD Million) 9.4.4.3. Rest of the Latin America 9.4.4.3.1. Rest of the Latin America Market, By Product, 2021 - 2030 (USD Million) 9.4.4.3.3. Rest of the Latin America Market, By Type, 2021 - 2030 (USD Million) 9.5. MEA 9.5.1. MEA Market, By Product, 2021 - 2030 (USD Million) 9.5.3. MEA Market, By Type, 2021 - 2030 (USD Million) 10. Competitive Landscape 10.1 Thermo Fisher Scientific, Inc. (US) 10.1.1. Company overview 10.1.2. Financial performance 10.1.3. Product Portfolio Analysis 10.1.4. Business Strategy & Recent Development 10.2. R&D Systems (US) 10.2.1. Company overview 10.2.2. Financial performance 10.2.3. Product Portfolio Analysis 10.2.4. Business Strategy & Recent Development 10.3. Abcam plc (UK) 10.3.1. Company overview 10.3.2. Financial performance 10.3.3. Product Portfolio Analysis 10.3.4. Business Strategy & Recent Development 10.4. Merck KGaA (Germany) 10.4.1. Company overview 10.4.2. Financial performance 10.4.3. Product Portfolio Analysis 10.4.4. Business Strategy & Recent Development 10.5. Proteintech Group, Inc. (US) 10.5.1. Company overview 10.5.2. Financial performance 10.5.3. Product Portfolio Analysis 10.5.4. Business Strategy & Recent Development 10.6. Janssen-Cilag Pty Ltd. 10.6.1. Company overview 10.6.2. Financial performance 10.6.3. Product Portfolio Analysis 10.6.4. Business Strategy & Recent Development 10.7. Aviva Systems Biology 10.7.1. Company overview 10.7.2. Financial performance 10.7.3. Product Portfolio Analysis 10.7.4. Business Strategy & Recent Development 10.8. Bio-Techne Corporation (US) 10.8.1. Company overview 10.8.2. Financial performance 10.8.3. Product Portfolio Analysis 10.8.4. Business Strategy & Recent Development 10.9. Elpiscience BioPharma 10.9.1. Company overview 10.9.2. Financial performance 10.9.3. Product Portfolio Analysis 10.9.4. Business Strategy & Recent Development List of Tables (65 Tables) TABLE 1. Market, By Product, 2021-2030 (USD Million) TABLE 2. Market FOR Growth factors (Blood and Tissue) and chemokines, BY REGION, 2021-2030 (USD Million) TABLE 3. Market FOR Structural proteins BY REGION, 2021-2030 (USD Million) TABLE 4. Market Kinase proteins, BY REGION, 2021-2030 (USD Million) TABLE 5. Market FOR Human insulin, BY REGION, 2021-2030 (USD Million) TABLE 6. Market FOR Regulatory proteins BY REGION, 2021-2030 (USD Million) TABLE 7. Market Membrane proteins, BY REGION, 2021-2030 (USD Million) TABLE 8. Market FOR Recombinant metabolic enzymes, BY REGION, 2021-2030 (USD Million) TABLE 6. Market FOR Adhesion molecules and receptors BY REGION, 2021-2030 (USD Million) TABLE 7. Market Immune response proteins , BY REGION, 2021-2030 (USD Million) TABLE 8. Market FOR Other s, BY REGION, 2021-2030 (USD Million) TABLE 6. Market, BY TYPE, 2021-2030 (USD Million) TABLE 7. Market FOR Biologics, BY REGION, 2021-2030 (USD Million) TABLE 8. Market FOR Vaccines, BY REGION, 2021-2030 (USD Million) TABLE 9. Market FOR Cell & gene therapy, BY REGION, 2021-2030 (USD Million) TABLE 10. Market, BY REGION, 2021-2030 (USD Million) TABLE 11. NORTH AMERICA Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 12. NORTH AMERICA Market, By Product, 2021-2030 (USD Million) TABLE 13. NORTH AMERICA Market, BY TYPE, 2021-2030 (USD Million) TABLE 14. EUROPE Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 15. EUROPE Market, By Product, 2021-2030 (USD Million) TABLE 16. EUROPE Market, BY TYPE, 2021-2030 (USD Million) TABLE 17. ASIA-PACIFIC Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 18. ASIA-PACIFIC Market, By Product, 2021-2030 (USD Million) TABLE 19. ASIA-PACIFIC Market, BY TYPE, 2021-2030 (USD Million) TABLE 20. LAMEA Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 21. LAMEA Market, By Product, 2021-2030 (USD Million) TABLE 22. LAMEA Market, BY TYPE, 2021-2030 (USD Million) TABLE 23. Thermo Fisher Scientific, Inc. (US): COMPANY SNAPSHOT TABLE 24. Thermo Fisher Scientific, Inc. (US): OPERATING SEGMENTS TABLE 25. R&D Systems (US): COMPANY SNAPSHOT TABLE 26. R&D Systems (US): OPERATING SEGMENTS TABLE 27. Abcam plc (UK): COMPANY SNAPSHOT TABLE 28. Abcam plc (UK): OPERATING SEGMENTS TABLE 29. Proteintech Group, Inc. (US):COMPANY SNAPSHOT TABLE 30. Proteintech Group, Inc. (US): OPERATING SEGMENTS TABLE 31. Janssen-Cilag Pty Ltd.COMPANY SNAPSHOT TABLE 32. Janssen-Cilag Pty Ltd. (US): OPERATING SEGMENTS TABLE 33. Aviva Systems Biology.: COMPANY SNAPSHOT TABLE 34. Aviva Systems Biology.: OPERATING SEGMENTS TABLE 35. Bio-Techne Corporation (US): COMPANY SNAPSHOT TABLE 36. Bio-Techne Corporation (US): OPERATING SEGMENTS TABLE 37. Elpiscience BioPharma: COMPANY SNAPSHOT TABLE 38. Elpiscience BioPharma: OPERATING SEGMENTS List of Figures (20 Figures) Figure 1 Market: Research Methodology Steps Figure 2 Research Design Figure 3 Breakdown of Primaries: Market Figure 4 Research Methodology: Hypothesis Building Figure 5 Market: Product-Based Estimation Figure 6 Top 13 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2020 Figure 8 Import Data for Recombinant Protein, By Country, 2016–2020 (USD Thousand) Figure 9 Export Data for Recombinant Protein, By Country, 2016–2020 (USD Thousand) Figure 10 Data Triangulation Methodology Figure 11 Market, By Product, 2019 vs. 2025 (USD Million) Figure 12 Market Share, By END-USER 2019 vs. 2025 Figure 13 Geographical Snapshot of the Market Figure 14 Growth factors (Blood and Tissue) and chemokinesto Witness Higher CAGR in Based on Product Segment during Forecast Period. Figure 15 Biologics to Witness Higher CAGR in Market for By Type during Forecast Period. Figure 16 North America Accounted for the Largest Share of the Market, By Regional Basis, in 2019 Figure 17 Market: Drivers, Restraints, Opportunities, and Challenges Figure 18 North America: Market Snapshot Figure 19 Asia Pacific: Market Snapshot Figure 20 Vendor Dive: Evaluation Overview